BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bilsborough J, Targan SR, Snapper SB. Therapeutic Targets in Inflammatory Bowel Disease: Current and Future. Am J Gastroenterol Suppl 2016;3:27-37. [DOI: 10.1038/ajgsup.2016.18] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Jung SY, Park J, Baek M, Kim G, Kim J, Zheng H, Kim J, Kang I, Kim D, Lee JI. Development of an oral bentonite-based modified-release freeze-dried powder of vactosertib: Pharmacokinetics and anti-colitis activity in rodent models of ulcerative colitis. International Journal of Pharmaceutics 2020;578:119103. [DOI: 10.1016/j.ijpharm.2020.119103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Stillhart C, Vučićević K, Augustijns P, Basit AW, Batchelor H, Flanagan TR, Gesquiere I, Greupink R, Keszthelyi D, Koskinen M, Madla CM, Matthys C, Miljuš G, Mooij MG, Parrott N, Ungell A, de Wildt SN, Orlu M, Klein S, Müllertz A. Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review. European Journal of Pharmaceutical Sciences 2020;147:105280. [DOI: 10.1016/j.ejps.2020.105280] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 37.0] [Reference Citation Analysis]
3 Ford CL, Wang Y, Morgan K, Boktor M, Jordan P, Castor TP, Alexander JS. Interferon-gamma depresses human intestinal smooth muscle cell contractility: Relevance to inflammatory gut motility disturbances. Life Sciences 2019;222:69-77. [DOI: 10.1016/j.lfs.2019.01.059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Hu Y, Xu F, Zhang R, Legarda D, Dai J, Wang D, Li H, Zhang Y, Xue Q, Dong G, Zhang H, Lu C, Mortha A, Liu J, Cravedi P, Ting A, Li L, Qi CF, Pierce S, Merad M, Heeger P, Xiong H. Interleukin-1β-induced IRAK1 ubiquitination is required for TH-GM-CSF cell differentiation in T cell-mediated inflammation. J Autoimmun 2019;102:50-64. [PMID: 31080014 DOI: 10.1016/j.jaut.2019.04.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Bryan MC, Rajapaksa NS. Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. J Med Chem 2018;61:9030-58. [DOI: 10.1021/acs.jmedchem.8b00667] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
6 Ling K, Wu H, Neish AS, Champion JA. Alginate/chitosan microparticles for gastric passage and intestinal release of therapeutic protein nanoparticles. Journal of Controlled Release 2019;295:174-86. [DOI: 10.1016/j.jconrel.2018.12.017] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 19.0] [Reference Citation Analysis]
7 Gely C, Marín L, Gordillo J, Mañosa M, Bertoletti F, Cañete F, González-Muñoza C, Calafat M, Domènech E, Garcia-Planella E. Impact of pain associated with the subcutaneous administration of adalimumab. Gastroenterol Hepatol 2020;43:9-13. [PMID: 31492425 DOI: 10.1016/j.gastrohep.2019.06.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
8 Ashton JJ, Beattie RM. Personalised therapy for inflammatory bowel disease. The Lancet 2019;393:1672-4. [DOI: 10.1016/s0140-6736(18)33125-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
9 Fernández-tomé S, Hernández-ledesma B, Chaparro M, Indiano-romacho P, Bernardo D, Gisbert JP. Role of food proteins and bioactive peptides in inflammatory bowel disease. Trends in Food Science & Technology 2019;88:194-206. [DOI: 10.1016/j.tifs.2019.03.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
10 Cheluvappa R. Identification of New Potential Therapies for Colitis Amelioration Using an Appendicitis-Appendectomy Model. Inflamm Bowel Dis 2019;25:436-44. [PMID: 30329049 DOI: 10.1093/ibd/izy332] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Ghosh S, Sanchez Gonzalez Y, Zhou W, Clark R, Xie W, Louis E, Loftus EV Jr, Panes J, Danese S. Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis. J Crohns Colitis 2021:jjab099. [PMID: 34107013 DOI: 10.1093/ecco-jcc/jjab099] [Reference Citation Analysis]
12 Liu W, Dong Z, Liu K, Lu Y, Wu W, Qi J, Chen Z. Targeting strategies of oral nano-delivery systems for treating inflammatory bowel disease. Int J Pharm 2021;600:120461. [PMID: 33711470 DOI: 10.1016/j.ijpharm.2021.120461] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Della Bella S, Calcaterra F, Bacci M, Carenza C, Pandolfo C, Ferrazzi P, Uva P, Pagani M, Lodigiani C, Mavilio D. Pathologic up-regulation of TNFSF15–TNFRSF25 axis sustains endothelial dysfunction in unprovoked venous thromboembolism. Cardiovascular Research 2020;116:698-707. [DOI: 10.1093/cvr/cvz131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Verma S, Ravichandiran V, Ranjan N, Flora SJS. Recent Advances in Therapeutic Applications of Bisbenzimidazoles. Med Chem 2020;16:454-86. [PMID: 31038072 DOI: 10.2174/1573406415666190416120801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]